JUN 06, 2022 2:03 AM PDT

Using Antibodies to Create Potent Cancer Treatments

WRITTEN BY: Carmen Leitch

Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes of cancer can differ greatly from one person to another, one reason why cases can be very difficult to treat. That is also why some therapeutic strategies seek to improve the ability of a cancer patient's own immune system to fight cancer by itself. Scientists have now developed an approach that utilizes antibodies from a patient to create cancer-killing autoantibodies.

Image credit: Pixabay

The immune system can already generate antibodies against tumor cells, and while those antibodies are excellent at identifying cancer, they are not powerful enough to destroy it. Reporting in Science Advances, researchers have converted both "off-the-shelf' and human antibodies into bi-specific antibodies, which makes them more potent.

Antibodies can identify specific antigens, molecules that sit on the surfaces of cells; it's how they identify foreign cells. Bispecific antibodies, or BiAbs can recognize two separate antigens simultaneously. They are more powerful than common, monoclonal antibodies, and there is less of a chance that cells will develop resistance to BiAbs.

In this work, researchers modified either commercially available antibodies - human immunoglobulin G (IgG), or patient antibodies with a signal that would bind to T cells. These T cell–redirecting autoantibodies (TRAAbs) are meant to bring T cells, immune cells that can kill tumors, in closer proximity with tumors, and increase the immune response against cancer. The TRAAbs were shown to be an effective therapeutic that sought to bind to tumor cells preferentially over healthy tissue.

Researchers have not successfully made bispecific antibodies from native antibodies before this. These BiAbs merge the specificity of a molecule from a patient, which is made by them and for them, with the cell-killing power of a T cell. The researchers are hopeful that these personalized therapeutics, which can be made in only hours, could work well against solid tumors.

"Much is yet to be done before this could be considered a practical clinical approach," cautioned study leader Andrew Tsourkas, a Professor in Bioengineering at the University of Pennsylvania. "But I hope at the very least this works stimulates new ideas in the way we think about personalized medicine."

After antibodies were carefully labeled with T cell targeting domains, the researchers tested them in a mouse model and cell lines. This work indicated that the TRAAbs bound to tumors.

Next, the researchers are planning to isolate anti-tumor antibodies from patient serum.  Such antibodies could possibly send the bispecific antibodies to other places in the body, and they want to know more about the potential for adverse or unintended consequences. While still in the early stages, this research opens up a new cancer treatment avenue.

Sources: University of Pennsylvania, Science Advances

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUN 01, 2022
Clinical & Molecular DX
Personalized Cancer Vaccine Showing Promise in Treating Melanoma and Ovarian Cancer
JUN 01, 2022
Personalized Cancer Vaccine Showing Promise in Treating Melanoma and Ovarian Cancer
Cancer vaccines have been around for decades, but a unique neoantigen vaccine called NeoVax is making researchers hopefu ...
JUN 06, 2022
Health & Medicine
Stagnant US Cervical Cancer Survival Rates
JUN 06, 2022
Stagnant US Cervical Cancer Survival Rates
According to JAMA Network, despite the overall cancer mortality rate decreasing since the 90s, cervical cancer survival ...
JUN 23, 2022
Clinical & Molecular DX
Accelerate diagnostic development with the right supplier
JUN 23, 2022
Accelerate diagnostic development with the right supplier
Diagnostic assays like the one you’re developing are in demand. But your task isn’t simple. Set yourself up ...
JUN 25, 2022
Immunology
A Link Between Hair Growth and the Immune System is Revealed
JUN 25, 2022
A Link Between Hair Growth and the Immune System is Revealed
Salk Institute researchers studying alopecia have learned more about the link between immunity and hair growth.
JUL 21, 2022
Clinical & Molecular DX
Best practices for lateral flow assay development
JUL 21, 2022
Best practices for lateral flow assay development
In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper ...
JUL 26, 2022
Clinical & Molecular DX
Researchers Recognize New Complicating Factor in Organ Transplantation
JUL 26, 2022
Researchers Recognize New Complicating Factor in Organ Transplantation
Organ transplantation is a life-saving measure that is often a last resort to treat end-stage organ failure. Organ trans ...
Loading Comments...